Marvell (MRVL) CFO expects the transaction to accelerate revenue growth and be accretive to non-GAAP gross and operating margins, inclusive of the USD 1bln-plus in run rate synergies it primarily sees from cogs

• Expect the combination to be accretive to non-GAAP EPS, starting in year one post-close.

Management commentary of this kind is standard fare on deal announcement calls: accretion claims from the acquirer's CFO are the rule rather than the exception, and the market has learned to discount them by the quality of the assumptions underneath. The load-bearing phrase is the synergy split, with the bulk of run-rate synergies said to come from cost of goods sold rather than opex, which in semiconductor combinations typically maps to overlapping supplier, foundry and packaging spend; COGS-led synergy stories have historically been harder to deliver on schedule than headcount-led ones, and their credibility rests on how much overlap actually exists in the respective cost structures. The non-GAAP framing throughout is worth flagging, as it excludes amortisation and stock-based compensation that are especially large in chip-sector deals, meaning GAAP dilution in early years is the established pattern even where adjusted figures show accretion. The near-term follow-ons are the conference call detail on synergy phasing and one-off integration costs, any disclosure on the financing mix since cash versus stock determines the dilution arithmetic, and the initial reaction of the target's holders and the peer set. Regulatory review timelines and customer concentration risk at the combined entity are the tells that have mattered in comparable semiconductor consolidations.